Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.chom.2021.02.019 http://scihub22266oqcxt.onion/10.1016/j.chom.2021.02.019 33657424!7904446!33657424     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Host+Microbe 2021 ; 29 (4): 551-563.e5 Nephropedia Template TP {{tp|p=33657424|t=2021. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies |pdf=|usr=}}{{33657424}} gab.com Text Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies JO: Cell Host Microbe http://www.kidney.de/pget.php?&tw=1&pmid=33657424 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by a burst in the upper respiratory portal for high transmissibility. To determine human neutralizing antibodies (HuNAbs) for entry protection, we tested three potent HuNAbs (IC(50) range, 0.0007-0.35 mug/mL) against live SARS-CoV-2 infection in the golden Syrian hamster model. These HuNAbs inhibit SARS-CoV-2 infection by competing with human angiotensin converting enzyme-2 for binding to the viral receptor binding domain (RBD). Prophylactic intraperitoneal or intranasal injection of individual HuNAb or DNA vaccination significantly reduces infection in the lungs but not in the nasal turbinates of hamsters intranasally challenged with SARS-CoV-2. Although postchallenge HuNAb therapy suppresses viral loads and lung damage, robust infection is observed in nasal turbinates treated within 1-3 days. Our findings demonstrate that systemic HuNAb suppresses SARS-CoV-2 replication and injury in lungs; however, robust viral infection in nasal turbinate may outcompete the antibody with significant implications to subprotection, reinfection, and vaccine. Twit Text FOAVip Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies ????Cell Host Microbe http://www.kidney.de/pget.php?&tw=1&pmid=33657424 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33657424 #FOAvip English Wikipedia <ref>{{Cite pmid|33657424}}</ref> Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies #MMPMID33657424 Zhou D; Chan JF; Zhou B; Zhou R; Li S; Shan S; Liu L; Zhang AJ; Chen SJ; Chan CC; Xu H; Poon VK; Yuan S; Li C; Chik KK; Chan CC; Cao J; Chan CY; Kwan KY; Du Z; Lau TT; Zhang Q; Zhou J; To KK; Zhang L; Ho DD; Yuen KY; Chen Z Cell Host Microbe 2021[Apr]; 29 (4): 551-563.e5 PMID33657424show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by a burst in the upper respiratory portal for high transmissibility. To determine human neutralizing antibodies (HuNAbs) for entry protection, we tested three potent HuNAbs (IC(50) range, 0.0007-0.35 mug/mL) against live SARS-CoV-2 infection in the golden Syrian hamster model. These HuNAbs inhibit SARS-CoV-2 infection by competing with human angiotensin converting enzyme-2 for binding to the viral receptor binding domain (RBD). Prophylactic intraperitoneal or intranasal injection of individual HuNAb or DNA vaccination significantly reduces infection in the lungs but not in the nasal turbinates of hamsters intranasally challenged with SARS-CoV-2. Although postchallenge HuNAb therapy suppresses viral loads and lung damage, robust infection is observed in nasal turbinates treated within 1-3 days. Our findings demonstrate that systemic HuNAb suppresses SARS-CoV-2 replication and injury in lungs; however, robust viral infection in nasal turbinate may outcompete the antibody with significant implications to subprotection, reinfection, and vaccine. |Angiotensin-Converting Enzyme 2/physiology[MESH] |Animals[MESH] |Antibodies, Neutralizing/immunology/*therapeutic use[MESH] |Antibodies, Viral/immunology/*therapeutic use[MESH] |COVID-19/immunology/*therapy/virology[MESH] |Cricetinae[MESH] |Female[MESH] |HEK293 Cells[MESH] |Humans[MESH] |Male[MESH] |Mesocricetus[MESH] |SARS-CoV-2/*immunology[MESH] |Turbinates/*virology[MESH]Robust SARS-CoV-2 infection in nasal turbinates after treatment with s(epmc).pdf DeepDyve Pubget Overpricing